In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provectus Biopharmaceuticals, Inc.

http://www.provectusbio.com/

Latest From Provectus Biopharmaceuticals, Inc.

Amylyx Steps Outside Neurodegenerative Disease With New Late-Stage Asset

The company outlined plans to develop newly acquired GLP-1 antagonist avexitide. CEOs Joshua Cohen and Justin Klee talked to Scrip about the strategy.

Deals Research & Development

AnGes To Withdraw, Refile HGF Gene Therapy In Japan

If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.

Japan Gene Therapy

AnGes To Withdraw, Refile HGF Gene Therapy In Japan

If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.

Japan Gene Therapy

Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens

Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Medical Devices
    • Laser
  • Other Names / Subsidiaries
    • Provectus Biopharmaceuticals Australia Pty Ltd.
    • Provectus Pharmaceuticals, Inc.
UsernamePublicRestriction

Register